


## PHARMACEUTICAL 2018

## KEMPHARM INC Rank 229 of 349







KEMPHARM INC Rank 229 of 349

The relative strengths and weaknesses of KEMPHARM INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KEMPHARM INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 91% points. The greatest weakness of KEMPHARM INC is the variable Revenues, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is -295%, being 17% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	46,996
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,509
Liabilities, Non-Current	794
Other Assets	3,456
Other Compr. Net Income	0
Other Expenses	-43
Other Liabilities	97,669
Other Net Income	-10,063
Property and Equipment	2,004
Research and Development	20,593
Revenues	0
Selling, General and Administrative Expense	12,773

Output Variable	Value in 1000 USD
Assets	52,456
Liabilities	109,972
Expenses	33,323
Stockholders Equity	-57,516
Net Income	-43,386
Comprehensive Net Income	-43,386
Economic Capital Ratio	-295%

